Spectral Med Inc is experiencing slight declines amid notable developments.
Spectral Med Inc (EDT.TO) has seen a decrease in its stock price this week, closing at C$1.36, down 1.48% on the day and 2.21% over the week. This follows a series of important corporate announcements that investors may want to consider as they evaluate the company's potential.
Advertisement
Get up to $2,000 cash back
Open and fund a new Qtrade account with promo code SPRING26. Offer ends July 31, 2026.
Spectral Med Inc
EDT.TO
EDT.TO
Spectral Med Inc
WealthAwesomeMarket cap
$396.12M
52W high
$1.76
52W low
$0.77
1W change
-2.21%
Beta
0.21
Analyst Price Targets
Based on analyst covering EDT
Wall Street analysts forecast EDT stock price to rise 136.8% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.15
+136.8% Upside
Current Price
C$1.33
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EDT's historical volatility
30-Day Vol
21.3%
Annualized
90-Day Vol
33.5%
Annualized
Trend (90d)
-15.5%
Annualized drift
90d Mean
C$1.26
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$1.31 | C$1.21 โ C$1.41 |
| 60 trading days | C$1.28 | C$1.16 โ C$1.42 |
| 90 trading days | C$1.26 | C$1.11 โ C$1.43 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Investor takeaway: While recent developments may suggest a positive outlook for Spectral Med, the stock's performance indicates caution. Investors should keep an eye on upcoming milestones, particularly regarding the PMA application with the FDA.
C$1.36 closing price, down 1.48% today.
The stock is currently trading at 60% of its 52-week range, indicating it may be undervalued relative to its past performance.
Bull case
The recent submission of the PMA application for PMX could lead to significant growth if approved. Analysts suggest this could mean a potential upside of 131.6%.
Bear case
Concerns arise from the company's negative profit margins and return on equity, especially in light of the recent stock performance and lower-than-average trading volume.
Recent Price Action
Spectral Med Inc has faced a challenging week, with its stock price closing at C$1.36, reflecting a 1.48% drop today and a total decline of 2.21% over the week. Year-to-date, the stock has also decreased by 3.62%. The volume of shares traded today was 23,789, which is below the 20-day average of 49,489 shares, indicating lower investor activity.
Company News and Developments
There have been several notable developments for Spectral Med Inc. On June 25, 2026, the company announced the submission of its Premarket Approval (PMA) application for PMX to the U.S. FDA. This is a crucial step that could significantly impact the company's future if the application is approved. Additionally, the company recently held its Annual and Special Meeting of Shareholders on June 9, 2026, where all proposed resolutions were approved.
Technical Picture
From a technical standpoint, Spectral Med Inc is trading slightly below its 50-day moving average of C$1.38 and its 200-day moving average of C$1.37, indicating a potential bearish trend. The stock's 52-week range is between C$0.77 and C$1.76, placing its current price at approximately 60% of this range. With a low beta of 0.21, the stock is less volatile compared to the broader market, which may appeal to conservative investors.
Insider Activity
No recent insider trading activity has been reported for Spectral Med Inc, suggesting a lack of significant insider confidence or concern at this time.
Conclusion
As of the latest close, Spectral Med Inc's stock stands at C$1.36, down 1.48% for the day. While the recent FDA filing for PMX may offer a bullish outlook, investors should remain cautious given the company's current performance metrics and the overall market conditions.
Advertisement
